From Hoops (I think) on the IHUB message board:
Post# of 36537
(Total Views: 265)
Posted On: 12/18/2018 9:08:13 AM
From Hoops (I think) on the IHUB message board:
I'm not a frequent poster, nor am I a stock professional. I'm a guy, like a lot of other guys, who enjoys managing a portion of his portfolio, and reserves a small amount of funds for spec stocks that appear to have a reasonable chance for success. So I'm providing this summary for amateurs like myself.
I don't know of any investor in Generex that has not been hurt financially. When it was on NASDAQ 12-13 years ago, the pps seemed to go up daily on PR's, which turned out to be puff pieces. The major decline started when Generex announced a launch of its buccal insulin delivery system, Rapid-Mist, in India, and the deal was sabotaged, mishandled, or fraudulent. Take your pick. At the time Generex had a wholly owned subsidiary, Antigen Express, which was testing its AE37 against metastatic breast cancer and other cancers. The entire company went down the tubes with its 1:1000 reverse split.
Joe Moscato, the current CEO, came on board in 2009 (I think), as I attended the ASM in NYC that year. He has been here during the worst years of Generex. He pushed hard for a R/S that would have kept Generex on NASDAQ, but the proposal was narrowly defeated. He stayed with the company and promised to do his best to bring the company back and reward long term shareholders, many of us who have held shares for more than 10 years.
Interestingly, buccal delivery and AE37 are still integral to the company. However, much more has been accomplished. If anyone wants to begin due diligence,go to the Generex Biotechnology website "News". Begin with the December 17, 2017 PR and read forward. You will find the vast majority of PR's between October 2018 and the present. The centerpiece was the 1:20 dividend, that went into effect on December 3, 2018. Most shareholders benefited. Those with ETrade and TD Ameritrade, not so well, due to problems with the transfer agent.
Much more progress is anticipated, but Generex remains a relatively small, speculative biotech company that is still OTC. IMO, Generex is still speculative. However, should it achieve its goal of uplisting to a more reputable exchange, it could develop into an investment. Mr. Moscato might argue that its already there. This really is an interesting stock for the "little guy", but it isn't for everyone. This is not a stock for your IRA, 401K, or to catch up on your retirement allocation, but it will keep you interested in investing and the stock market.
These are my own thoughts and recollections. In no way is this intended as pump 'n dump. I believe most people recognize pump 'n dump when they read it. As always, do your own DD.
I'm not a frequent poster, nor am I a stock professional. I'm a guy, like a lot of other guys, who enjoys managing a portion of his portfolio, and reserves a small amount of funds for spec stocks that appear to have a reasonable chance for success. So I'm providing this summary for amateurs like myself.
I don't know of any investor in Generex that has not been hurt financially. When it was on NASDAQ 12-13 years ago, the pps seemed to go up daily on PR's, which turned out to be puff pieces. The major decline started when Generex announced a launch of its buccal insulin delivery system, Rapid-Mist, in India, and the deal was sabotaged, mishandled, or fraudulent. Take your pick. At the time Generex had a wholly owned subsidiary, Antigen Express, which was testing its AE37 against metastatic breast cancer and other cancers. The entire company went down the tubes with its 1:1000 reverse split.
Joe Moscato, the current CEO, came on board in 2009 (I think), as I attended the ASM in NYC that year. He has been here during the worst years of Generex. He pushed hard for a R/S that would have kept Generex on NASDAQ, but the proposal was narrowly defeated. He stayed with the company and promised to do his best to bring the company back and reward long term shareholders, many of us who have held shares for more than 10 years.
Interestingly, buccal delivery and AE37 are still integral to the company. However, much more has been accomplished. If anyone wants to begin due diligence,go to the Generex Biotechnology website "News". Begin with the December 17, 2017 PR and read forward. You will find the vast majority of PR's between October 2018 and the present. The centerpiece was the 1:20 dividend, that went into effect on December 3, 2018. Most shareholders benefited. Those with ETrade and TD Ameritrade, not so well, due to problems with the transfer agent.
Much more progress is anticipated, but Generex remains a relatively small, speculative biotech company that is still OTC. IMO, Generex is still speculative. However, should it achieve its goal of uplisting to a more reputable exchange, it could develop into an investment. Mr. Moscato might argue that its already there. This really is an interesting stock for the "little guy", but it isn't for everyone. This is not a stock for your IRA, 401K, or to catch up on your retirement allocation, but it will keep you interested in investing and the stock market.
These are my own thoughts and recollections. In no way is this intended as pump 'n dump. I believe most people recognize pump 'n dump when they read it. As always, do your own DD.
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼